Morgan Stanley: Slightly raised the target price of Pharmaron (03759) to HKD 31.5, rating 'Overweight'
According to Zhitong Finance APP, Morgan Stanley released a research report stating that it updated the risk-return profile of Pharmaron (03759) $PHARMARON (03759.HK)$ ; The target price was increased from HKD 31 to HKD 31.5, with a rating of 'Overweight'. The bank adjusted its earnings forecasts for 2026 to 2030 by less than 1% to 3% in response to the group's 2025 performance, reflecting higher revenue expectations.
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Comments
to post a comment
1